Last reviewed · How we verify

NCT04907149

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970

Completed Phase 1 Last updated 23 July 2021
What this trial tests

Phase 1 trial testing GLPG3970 film-coated tablet in Healthy in 6 participants. Completed in 12 July 2021.

Timeline
7 June 2021
Primary endpoint
12 July 2021
12 July 2021

Quick facts

Lead sponsorGalapagos NV
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposebasic science
Enrollment6
Start date7 June 2021
Primary completion12 July 2021
Estimated completion12 July 2021
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Galapagos NV — full company profile →

Who can join

Adults 30 to 64, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study in healthy male volunteers to assess how the radiolabelled test medicine is taken up and broken down by the body when given by short infusion into a vein and when given by the mouth in the form of a tablet and an oral solution.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of GLPG3970 film-coated tablet

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Galapagos NV trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04907149.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing